In the United States, American Heart Month is observed in February to raise awareness about cardiovascular disease, the leading cause of death worldwide. To a similar end, Endocrine News focuses on a few recent journal studies that take a closer look at the impacts of incretin-based therapies in the setting of obesity and impaired cardiovascular health, as well as how they affect the liver, quality of life, insulin resistance, and much more.
February is heart month at Endocrine News , making it an opportune time to examine four recent studies that explore various aspects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and related incretin-based therapies, given obesity’s profound impact on cardiovascular health. Recent advances in obesity pharmacotherapy have shown unprecedented efficacy in weight reduction and cardiometabolic improvement.
GLP-1RAs (and their offshoots that add agonists of other key metabolic regulation substances) have shown particular promise in patients with obesity-related cardiovascular and metabolic complications, offering synergistic benefits that extend beyond weight loss.
Endocrine News published a clinical update in Research Highlights on 13 Feb 2026.
The item focuses on Beyond the Scale: What Else Glucagon-like Peptide-1 Receptor Agonists Can Do.
Review the original article for the full source wording and details.